SureTrader SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Oramed Pharmaceuticals (ORMP)

ORMP RSS Feed
Add ORMP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 8/10/2015 1:14:53 PM - Followers: 23 - Board type: Free - Posts Today: 0




Oramed's POD™ (Protein Oral Delivery) technology is capable of significantly enhancing the absorption of peptides and proteins across the intestinal wall when delivered orally without modifying the active compounds. POD technology is based on incorporating several components or adjuvants consisting entirely of registered pharmacopoeial or GRAS excipients with a long history of pharmaceutical use in the formulation.


These adjuvants are intended to protect the active peptide or protein while in transit through the harsh chemical environment of the gastrointestinal tract and promote its transport across the intestinal wall and into the general blood circulation once it has reached an absorptive surface. The precise choice of adjuvants and their composition stoichiometry in relation to the active component and to each other in the formulation, forms the basis of this novel technology and its intellectual property estate.

Nadav Kidron, Esq
 
Chief Executive Officer, President & Director
 
Mr. Kidron serves as Chief Executive Officer & Director of Oramed Pharmaceuticals, which he co-founded in 2006.

 

Mr. Kidron is an entrepreneur whose experience includes senior executive roles in a wide range of industries.

He is a member on the Board of Directors of Entera Bio, which started as a joint venture formed by Oramed and DNA Biomedical Solutions; and an international lecturer on Israel’s entrepreneurial culture and the country’s roots as an oasis of innovative ideas.

He holds a bachelors degree in law and an international masters in business administration, both from Bar-Ilan University in Israel. Mr. Kidron is a fellow of the Merage Business Executive Leadership Program and a member of the Israeli Bar Association.

 
Miriam Kidron, Ph.D
 
Chief Scientific Officer & Director
 
Dr. Kidron serves as Chief Scientific Officer and Director of Oramed Pharmaceuticals, which she co-founded in 2006.

 

Dr. Kidron is a pharmacologist and biochemist, who earned her PhD in biochemistry from the Hebrew University of Jerusalem.

For close to 20 years, Dr. Kidron has been a senior researcher in the Diabetes Unit at Hadassah-Hebrew University Medical Center in Jerusalem, Israel, earning the Bern Schlanger Award for her work on diabetes research.

She was formerly a visiting professor at the Medical School at the University of Toronto and is a member of the American, European and Israeli Diabetes Associations.

 
Yifat Zommer, CPA
 
Chief Financial Officer
 
Ms. Zommer serves as Chief Financial Officer of Oramed Pharmaceuticals. She joined Oramed in 2009, bringing with her financial management experience with publicly traded and private companies in the high-tech sector.

 

She previously served as CFO for Witech Communications Ltd and CTWARE Ltd. Prior to that, she was an audit manager at Kesselman & Kesselman, a member of PwC, where she served for five years.

Ms. Zommer holds a bachelors degree in accounting and economics from The Hebrew University, a masters of business administration (MBA) from Tel-Aviv University and a masters degree in law (LL.M.) from Bar-Ilan University.

She is a certified public accountant (CPA) in Israel.

 
Josh Hexter
 
Chief Operating Officer, VP Business Development
 
Mr. Hexter serves as Chief Operating Officer and Vice President of Business Development of Oramed Pharmaceuticals, which he joined in 2013.

 

He brings to Oramed more than 15 years of prominent leadership, business development, operations know-how and management in the life science sector.

Mr. Hexter was most recently Executive Director of Corporate In-Licensing at BioLineRx (NASDAQ: BLRX).

Prior to joining BioLineRx, he worked in private equity and venture capital where he served as CEO of a VC-backed startup. As CEO of Biosensor Systems Design, Mr. Hexter was instrumental in shaping the company’s strategic focus and in forging business development agreements with Fortune 100 companies in the areas of food safety, medical diagnostics and homeland security.

Mr. Hexter earned a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.

For a more in-depth description of Oramed's POD technology,please click here.     
 
About Oramed

Oramed Pharmaceuticals (NASDAQCM:ORMP) was established in 2006, and is based on over 30 years of medical research at the world-renowned Hadassah University Medical Center in Jerusalem, Israel.

For over two decades, scientists at Hadassah Hospital's Diabetes Unit, led by Professor Hanoch Bar-On, worked to develop a technology designed to enable the oral administration of insulin to diabetics.  A medical breakthrough in 2005 laid the foundation for the founding of Oramed Pharmaceuticals, of which Hadassah remains a part owner. Professor Bar-On helped found Oramed, together with Dr. Miriam Kidron, and served as a director until his untimely death in 2006.

From the time of the company’s inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an oral insulin capsule, ORMD-0801, and an oral exenatide (a GLP-1 Analog) capsule, ORMD-0901. Combination therapy (ORMD 0801+0901) showed promising results in pre-clinical trials, and clinical trials are expected to follow. 

Oramed's unique oral delivery technology serves as a platform for other vaccines and medications currently available in injection form. The company is approached by pharmaceutical companies large and small looking to test compliance with Oramed’s technology on their product pipeline.

Oramed has garnered worldwide support of prominent scientists to its scientific advisory board, a testament to its sound technology:  the former Senior VP of Pfizer, Dr. Michael Berelowitz; Prof. John Amatruda, former Senior VP of Merck and Co.; Prof. Ele Ferrannini, Past President of the EASD*; and Prof. Avram Hershko, 2004 Nobel Prize Laureate in Chemistry, and a leader in the field of drug delivery methods, among others. The office of the Chief Scientist of Israel has also shown its confidence in Oramed’s technology, having awarded Oramed its third consecutive grant to continue its research.

Recent and promising developments at Oramed also include 5 patent approvals for its technologies in the Israeli, Japanese, Australian, and New Zealand Patent Offices. Patent approval is particularly important as it validates Oramed’s technology, establishing an international stronghold for its oral protein delivery methods. Oramed has an additional 34 pending patents and expects to see more of them approved in the future. 
                                                                                                                     

Overview of  Product Status:

  • ORMD-0801: FDA clearance to proceed with Phase 2 trials in the US under IND (Investigational New Drug application) as of May 2013. Trial to commence shortly.
    ORMD-0901: Trials on healthy volunteers (Phase Ib) and type 2 diabetic patients (Phase IIa) currently underway after successful pre-clinical and Phase Ia results.
    Combination Therapy (ORMD-0801+0901): An abstract of pre-clinical results was presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in June, 2012. Clinical trials expected to follow.

* European Association for the Study of Diabetes is the European equivalent of the American Diabetes Association (ADA)

 
About Oramed

Oramed Pharmaceuticals (NASDAQCM:ORMP) was established in 2006, and is based on over 30 years of medical research at the world-renowned Hadassah University Medical Center in Jerusalem, Israel.

For over two decades, scientists at Hadassah Hospital's Diabetes Unit, led by Professor Hanoch Bar-On, worked to develop a technology designed to enable the oral administration of insulin to diabetics.  A medical breakthrough in 2005 laid the foundation for the founding of Oramed Pharmaceuticals, of which Hadassah remains a part owner. Professor Bar-On helped found Oramed, together with Dr. Miriam Kidron, and served as a director until his untimely death in 2006.

From the time of the company’s inception, Oramed has successfully tested its technology via various animal and human studies on its two flagship products, an oral insulin capsule, ORMD-0801, and an oral exenatide (a GLP-1 Analog) capsule, ORMD-0901. Combination therapy (ORMD 0801+0901) showed promising results in pre-clinical trials, and clinical trials are expected to follow. 

Oramed's unique oral delivery technology serves as a platform for other vaccines and medications currently available in injection form. The company is approached by pharmaceutical companies large and small looking to test compliance with Oramed’s technology on their product pipeline.

Oramed has garnered worldwide support of prominent scientists to its scientific advisory board, a testament to its sound technology:  the former Senior VP of Pfizer, Dr. Michael Berelowitz; Prof. John Amatruda, former Senior VP of Merck and Co.; Prof. Ele Ferrannini, Past President of the EASD*; and Prof. Avram Hershko, 2004 Nobel Prize Laureate in Chemistry, and a leader in the field of drug delivery methods, among others. The office of the Chief Scientist of Israel has also shown its confidence in Oramed’s technology, having awarded Oramed its third consecutive grant to continue its research.

Recent and promising developments at Oramed also include 5 patent approvals for its technologies in the Israeli, Japanese, Australian, and New Zealand Patent Offices. Patent approval is particularly important as it validates Oramed’s technology, establishing an international stronghold for its oral protein delivery methods. Oramed has an additional 34 pending patents and expects to see more of them approved in the future. 

Overview of  Product Status:

  • ORMD-0801: FDA clearance to proceed with Phase 2 trials in the US under IND (Investigational New Drug application) as of May 2013. Trial to commence shortly.
    ORMD-0901: Trials on healthy volunteers (Phase Ib) and type 2 diabetic patients (Phase IIa) currently underway after successful pre-clinical and Phase Ia results.
    Combination Therapy (ORMD-0801+0901): An abstract of pre-clinical results was presented at the 72nd Scientific Sessions of the American Diabetes Association (ADA) in June, 2012. Clinical trials expected to follow.

* European Association for the Study of Diabetes is the European equivalent of the American Diabetes Association (ADA)

 

Oral Insulin Capsule

Injectable insulins are generally administered during the late stages of Type 2 diabetes mellitus (T2DM), when the pancreas can no longer produce insulin - leaving the patient insulin-dependent for life. Curbing disease progression is thus paramount to increasing patient quality of life and independence.

Current research has shown that administration of insulin at earlier stages of T2DM has positive effects, and is now beginning to be included in standard treatment regimens. While the benefits can be significant, some patients are still hesitant to introduce injections into their daily routine, especially when earlier stages of the disease tend to induce mild symptoms, easily disregarded by patients.

Oramed's oral insulin is indicated for the earlystages of T2DM, when it can still slow the rate of degeneration of the disease by providing additional insulin to the body and allowing pancreatic respite.

Orally administered insulin has the potential benefit of enhanced patient compliance at this crucial stage. Moreover, oral insulin has the added benefit of mimicking insulin's natural location and gradients in the body by first passing through the liver before entering the bloodstream.[1]

The insulin undergoes first-pass metabolism in the liver yielding physiologically relevant insulin concentrations for systemic circulation. By such means fewer or no hypoglycemic episodesoccur. This stands in sharp contrast tothe sometimes fatal side effects of injectable insulin, wherein the insulin may be circulating at dangerously high doses as a result of being delivered directly into the systemic circulation, thus bypassing the body's natural metabolic mechanisms.

ORMD-0801: A Note on Type 1 Diabetes Mellitus (T1DM)

Today, T1DM, formerly known as juvenile diabetes, affects both young and adult populations. In this form of the disease, an autoimmune reaction destroys the body's insulin-producing cells in the pancreas. In this form of the disease, insulin must be provided from an external source.

Oramed proposes to introduce ORMD-0801 treatment as a complementary agent to insulin injections in the treatment of T1DM. Such a treatment regimen will allow for fewer daily injections and has been shown to lower the frequency of blood glucose fluctuations in cases of unstable T1DM.

ORMD-0801: Current Status

Indication: type 2 diabetes

Indication: type 1 diabetes

ORMD-0801: Clinical Trial History

www.oramed.com/ufiles/P2a Data 30-Jan-2014.pdf

Press Center | Terms & Conditions | Privacy Statement Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed
 
 
 
ORMP [NASD]
Oramed Pharmaceuticals Inc.
Healthcare | Biotechnology | Israel
Index - P/E - EPS (ttm) -0.59 Insider Own 6.37% Shs Outstand 7.94M Perf Week 10.45%
Market Cap 175.42M Forward P/E 48.02 EPS next Y 0.46 Insider Trans - Shs Float 7.65M Perf Month 43.16%
Income -4.40M PEG - EPS next Q -0.18 Inst Own 0.70% Short Float 1.95% Perf Quarter 234.70%
Sales - P/S - EPS this Y -3.50% Inst Trans 19.32% Short Ratio 0.25 Perf Half Y 210.69%
Book/sh 0.92 P/B 24.01 EPS next Y - ROA -64.00% Target Price 28.50 Perf Year 198.92%
Cash/sh 0.98 P/C 22.49 EPS next 5Y - ROE -71.00% 52W Range 5.00 - 31.73 Perf YTD 43.16%
Dividend - P/FCF - EPS past 5Y 2.80% ROI - 52W High -30.38% Beta 0.77
Dividend % - Quick Ratio 11.40 Sales past 5Y - Gross Margin - 52W Low 341.80% ATR 3.31
Employees - Current Ratio 11.40 Sales Q/Q - Oper. Margin - RSI (14) 54.15 Volatility 16.81% 15.13%
Optionable Yes Debt/Eq 0.00 EPS Q/Q 0.00% Profit Margin - Rel Volume 1.12 Prev Close 24.94
Shortable Yes LT Debt/Eq 0.00 Earnings - Payout - Avg Volume 594.37K Price 22.09
Recom 2.00 SMA20 -3.84% SMA50 51.53% SMA200 140.45% Volume 666,211 Change -11.43%
 30-Jan-14           Reiterated                                Aegis Capital                                 Buy                                                 $30 →  $35
 08-Jan-14           Reiterated                                Aegis Capital                                 Buy                                                 $25 →  $30
 08-Jan-14            Initiated                                    MLV & Co                                        Buy                                                 $27
                             03-Dec-13           Initiated                                   Aegis Capital                                   Buy                                                 $25                                                                                     

31-Jan-14 06:00AM  

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown at TheStreet -11.43%
30-Jan-14 02:17PM   Oramed's oral insulin tests are positive, but investors are skittish at MarketWatch
11:31AM   ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events EDGAR Online
10:04AM   Israel's Oramed a step closer in race for first insulin pill Reuters
07:58AM   Oral Diabetes Medicine Shows Promise in Study of Oramed Pill at Bloomberg
04:00AM   Oramed Announces Successful FDA Phase 2a Clinical Trial Results PR Newswire
28-Jan-14 12:04PM   Midday movers: Apple, Facebook, Waters & More at CNBC
07:48AM   Oramed's Data Will Define A New Standard For Diabetes at Seeking Alpha
27-Jan-14 08:48PM   Oramed Pharmaceuticals: Mondays Top Stock at Motley Fool +21.90%
09:10AM   Oramed to Announce Results of its Phase 2a Clinical Trial for Oral Insulin on January 30th at the Tel Aviv Stock Exchange PR Newswire
21-Jan-14 01:07PM   3 Small Biotech Companies Poised For Big Growth In 2014 at Seeking Alpha
01:07PM   3 Small Biotech Companies Poised For Big Growth In 2014
18-Jan-14 01:04PM   ORAMED PHARMACEUTICALS INC. Financials EDGAR Online Financials
01:04PM   ORAMED PHARMACEUTICALS INC. Financials
17-Jan-14 06:03PM   Nasdaq stocks posting largest percentage decreases AP
01:33PM   Nasdaq stocks posting largest percentage decreases AP
16-Jan-14 06:02PM   Nasdaq stocks posting largest percentage decreases AP
01:31PM   Nasdaq stocks posting largest percentage decreases AP
15-Jan-14 06:06PM   Nasdaq stocks posting largest percentage decreases AP -13.10%
06:06PM   Nasdaq stocks posting largest percentage decreases
01:35PM   Nasdaq stocks posting largest percentage decreases AP
14-Jan-14 06:12PM   Six Israeli Biotech New Issues Set A Blistering Pace at Investor's Business Daily
06:12PM   Six Israeli Biotech New Issues Set A Blistering Pace
03:34PM   ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
03:34PM   ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report
09-Jan-14 11:13AM   Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better at TheStreet
11:13AM   Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better
08-Jan-14 01:32PM   Nasdaq stocks posting largest percentage increases AP +31.34%
02:45AM   Coverage initiated on Oramed Pharmaceuticals by MLV & Co Briefing.com
02:45AM   Coverage initiated on Oramed Pharmaceuticals by MLV & Co
03-Jan-14 06:03PM   Nasdaq stocks posting largest percentage increases AP
01:22PM   Nasdaq stocks posting largest percentage increases AP
02-Jan-14 06:03PM   Nasdaq stocks posting largest percentage increases AP +17.95%
01:34PM   Nasdaq stocks posting largest percentage increases AP
08:20AM   Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins PR Newswire
08:20AM   Oramed Receives Patent Allowance in Israel and Australia for Platform Technology in Oral Delivery of Proteins
26-Dec-13 09:21AM   ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online -21.27%
09:21AM   ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and
24-Dec-13 09:12PM   Oramed to Raise $15,800,000 in Registered Direct Offering PR Newswire +28.10%
09:12PM   Oramed to Raise $15,800,000 in Registered Direct Offering
05:53PM   Nasdaq stocks posting largest volume increases AP
20-Dec-13 07:30AM   Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes PR Newswire +48.95%
07:30AM   Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes
12-Dec-13 06:04PM   Nasdaq stocks posting largest percentage decreases AP +7.93%
01:24PM   Nasdaq stocks posting largest percentage decreases AP
11-Dec-13 06:22PM   Nasdaq stocks posting largest percentage decreases AP -10.97%
10-Dec-13 01:04PM   ORAMED PHARMACEUTICALS INC. Financials EDGAR Online Financials
01:04PM   ORAMED PHARMACEUTICALS INC. Financials
10:37AM   Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel PR Newswire
10:37AM   Oramed Receives Allowance on its Core Oral GLP-1 Technology Patent in Israel
03-Dec-13 09:28AM   Coverage initiated on Oramed Pharmaceuticals by Aegis Capital Briefing.com
27-Nov-13 04:40PM   ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report EDGAR Online
04:40PM   ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
19-Nov-13 09:58AM   InPlay: Oramed Pharmaceuticals receives patent in the European Union for the oral delivery of insulin Briefing.com
09:57AM   Oramed Receives Patent in the European Union for the Oral Delivery of Insulin PR Newswire
09:57AM   Oramed Receives Patent in the European Union for the Oral Delivery of Insulin
12-Nov-13 10:15AM   InPlay: Oramed Pharmaceuticals announces last patient out in Phase 2a FDA trial of its ORMD-0801 oral insulin capsule Briefing.com
10:12AM   Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule PR Newswire
10:12AM   Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule
22-Oct-13 03:02PM   Oramed in talks with big pharma on oral insulin product, Bloomberg says theflyonthewall.com
03-Oct-13 11:15AM   InPlay: Oramed Pharmaceuticals receives two additional patent approvals for its platform Protein Oral Delivery technology in Japan and Canada Briefing.com
11:13AM   Oramed Granted Patents in Japan and Canada for its POD Technology for the Oral Delivery of Proteins PR Newswire
25-Sep-13 08:10AM   Oramed to Participate in Barclays' Israel Biotech Corporate Day in Zurich on September 30, 2013 PR Newswire
22-Sep-13 06:30AM   Companies Race To Develop The Next Novel Blockbuster Diabetes Drug at Seeking Alpha
17-Sep-13 08:12AM   InPlay: Oramed Pharmaceuticals' Platform Technology in oral delivery of proteins receives patent in Russia Briefing.com
08:10AM   Oramed's Platform Technology in Oral Delivery of Proteins Receives Patent in Russia PR Newswire
10-Sep-13 08:14AM   InPlay: Oramed Pharmaceuticals granted patent in China for its platform technology in oral delivery of proteins Briefing.com
08:10AM   Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins PR Newswire
03-Sep-13 08:12AM   InPlay: Oramed Pharmaceuticals submits Pre-IND package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 analog for the treatment of Type 2 diabetes Briefing.com
08:10AM   Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes PR Newswire
29-Aug-13 02:19PM   [video] Quick Take: Revolutionizing Diabetes Treatment at TheStreet
12:26PM   [video] Seeking to Remake Diabetes Therapy at TheStreet
12:26PM   [video] Revolutionizing Diabetes Treatment at TheStreet
27-Aug-13 10:00AM   Oramed Pharmaceuticals Inc. [ORMP] to Ring The NASDAQ Stock Market Closing Bell GlobeNewswire
21-Aug-13 08:16AM   Oramed initiates patent recruitment for ORMD-0801 clinical trial theflyonthewall.com
08:10AM   Oramed Initiates Patient Recruitment for a New Clinical Trial in Israel of its Oral Insulin Drug ORMD-0801 in the Treatment of Type 1 Diabetes PR Newswire
05-Aug-13 04:29PM   Oramed Expands Diabetes Platform With Oral GLP-1 Agonist at Seeking Alpha
31-Jul-13 11:49PM   ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
30-Jul-13 08:12AM   InPlay: Oramed Pharmaceuticals submits Pre-IND meeting request to fDA for its oral exenatide capsule ORMD-0901 Briefing.com +6.47%
08:10AM   Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901 PR Newswire
23-Jul-13 01:04PM   ORAMED PHARMACEUTICALS INC. Financials EDGAR Online Financials
17-Jul-13 12:40PM   Oramed: An Early-Stage Biotech Company With Huge Potential at Seeking Alpha
09:14AM   ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
11-Jul-13 02:21AM   ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online -5.29%
10-Jul-13 06:00PM   Oramed Pharmaceuticals to raise $4.6M in registered direct offering at theflyonthewall.com
06:00PM   InPlay: Oramed Pharmaceuticals to raise $4.6 mln in registered direct offering of ~657k shares Briefing.com
05:58PM   Oramed to Raise $4,600,000 in Registered Direct Offering PR Newswire
01:47PM   Nasdaq stocks posting largest percentage decreases AP
09-Jul-13 07:01PM   Nasdaq stocks posting largest percentage decreases AP -13.95%
01:16PM   Nasdaq stocks posting largest percentage decreases AP
08-Jul-13 01:24PM   Nasdaq stocks posting largest percentage decreases AP -10.27%
08:17AM   Oramed Pharmaceuticals enrolls first patient in Phase 2a oral insulin trial at theflyonthewall.com
08:17AM   InPlay: Oramed Pharmaceuticals enrolls first patient in its phase 2a u.s. oral insulin clinical trial Briefing.com
08:15AM   Oramed Enrolls First Patient in its Phase 2a U.S. Oral Insulin Clinical Trial PR Newswire
05-Jul-13 01:19PM   Nasdaq stocks posting largest percentage decreases AP +16.15%
02-Jul-13 01:19PM   Nasdaq stocks posting largest percentage decreases AP -11.12%
12:38PM   Oramed to Present at the 8th Annual JMP Securities Healthcare Conference in New York City PR Newswire
28-Jun-13 06:06PM   Nasdaq stocks posting largest percentage increases AP
01:30PM   Nasdaq stocks posting largest percentage increases AP
27-Jun-13 06:04PM   Nasdaq stocks posting largest percentage increases AP +6.54%
Oramed Pharmaceuticals, Inc., a development stage pharmaceutical company, is engaged in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company's product portfolio includes ORMD0801, an oral insulin capsule that is in Phase II clinical trials for the treatment of diabetes; and ORMD0901, an analog for GLP-1 gastrointestinal hormone, which is in pre-clinical trials. Its portfolio of product candidates is based on intellectual property that allows for the protection of proteins and polypeptides in the stomach, and for their absorption through the gastrointestinal wall. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in Jerusalem, Israel.
 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ORMP
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#411   ORMP Chart conix 08/10/15 01:14:53 PM
#410   $ORMP recent news/filings stocktrademan 07/27/15 01:01:40 PM
#409   Great chart, osprey conix 07/08/15 08:10:51 AM
#408   $ORMP Chart - closed above the 50, 100 ospreyeye 07/06/15 12:33:30 AM
#407   Yes! Time to accumulate! conix 07/02/15 05:23:27 PM
#406   ORMP nice move here today .. grabbed at Strukture 07/02/15 11:14:45 AM
#405   Is it a good time to accumulate more? rb14 05/06/15 09:36:27 PM
#404   Why slowly decaying? rb14 05/06/15 12:20:03 PM
#403   ready for the next leg!!!! moon walker Cubanwinner 04/28/15 11:55:51 AM
#402   ORMP can bounce from this levels Cubanwinner 04/24/15 08:55:03 AM
#401   All is about faith my friend!! Cubanwinner 04/16/15 09:25:34 AM
#400   I never believe 12 month target prices that conix 04/16/15 09:21:51 AM
#399   i want to see that $30 PPS....this year....i Cubanwinner 04/15/15 11:01:10 PM
#398   i still Holding from the beginning....adding in every deep Cubanwinner 04/15/15 11:18:19 AM
#397   who's still bagholding this - slow death to JohnDee123 04/15/15 09:52:41 AM
#396   I agree cheche770 04/14/15 03:38:58 PM
#395   $30 Target price? Pretty aggressive. conix 04/14/15 08:04:53 AM
#394   Can some please post the research report here? conix 04/13/15 08:12:34 PM
#393   RSI is pretty high. Pullback from here should conix 04/13/15 02:49:24 PM
#392   Yes My friend ORMP is HUgE up today!!!!WEeeeeeeeeeeee$$$ Cubanwinner 04/13/15 02:30:17 PM
#391   ORMP chart conix 04/13/15 02:22:43 PM
#390   $ORMP recent news/filings stocktrademan 04/13/15 01:34:22 PM
#389   Quarterly Report (10-q) Cubanwinner 04/06/15 07:04:59 AM
#388   April 3 2015 The 10Q filling Cubanwinner 04/03/15 08:13:43 PM
#387   Nice Close ORMP!!!$$ Cubanwinner 04/01/15 06:39:28 PM
#386   Yes we moving up this morning!!$10 soon Cubanwinner 03/31/15 09:53:55 AM
#385   bottom level$$$$ORMP will be trading above $10 soon Cubanwinner 03/30/15 11:28:22 AM
#384   ORMP is holding the price very well!!$10+ soon Cubanwinner 03/30/15 08:28:55 AM
#383   6.38 back in..... Cubanwinner 03/27/15 01:42:33 PM
#382   Oral insulin pill is based on EMIS;s Eligen technology. gamesetmatch101 03/26/15 11:56:17 AM
#381   $10 coming soon Cubanwinner 03/26/15 11:44:53 AM
#380   ORMP $10+ coming!!! Cubanwinner 03/26/15 11:10:25 AM
#379   Thanks. Always looking for the trade. oxnous 03/25/15 06:52:25 PM
#378   Would be interesting to know how many of Citrati 03/25/15 03:32:53 PM
#377   Everybody is wondering what the news is. ORMP conix 03/25/15 01:54:38 PM
#376   Zqueeseee!!! money$$$ ORMP Cubanwinner 03/25/15 11:59:03 AM
#375   Today Bloodbad Packardbell 03/25/15 11:35:16 AM
#374   Today will be another excellent day ORMP$$ Cubanwinner 03/25/15 09:15:14 AM
#373   nice green Tonyeight 03/24/15 05:33:51 PM
#372   Well, you just earned a member mark from Nomad505 03/24/15 05:19:29 PM
#371   Phase 2IIb Nice News Packardbell 03/24/15 04:24:00 PM
#370   yes!!! we did it three times!!! from 7.20 Cubanwinner 03/24/15 03:07:25 PM
#369   Huge move up!!!!! 8+ coming back!! Cubanwinner 03/24/15 01:09:31 PM
#368   Nice play to short.....ORMP$$ Cubanwinner 03/24/15 12:02:18 PM
#367   I look for bottom reversals like this. High oxnous 03/24/15 11:57:15 AM
#366   crazy move, looks like shorts moving in now. runningwithscissors 03/24/15 11:05:06 AM
#365   Most likely some type of news leaked but Citrati 03/24/15 10:54:02 AM
#364   Great call, oxnous! What a run. conix 03/24/15 10:42:07 AM
#363   Cant find any info either. Most likely some Tdash 03/24/15 10:39:32 AM
#362   Nice movement yesterday and today-reconranger reconranger 03/24/15 10:36:33 AM
PostSubject